News & Publications

In the Spotlight: A Personal Side of Our CEO

In the Spotlight: A Personal Side of Our CEO

By Torpedo / 25th July, 2025

Read more
Swiss Rockets Featured in Finanz und Wirtschaft: Strong Industry Recognition and Promising Clinical Outlook

Swiss Rockets Featured in Finanz und Wirtschaft: Strong Industry Recognition and Promising Clinical Outlook

By Torpedo / 16th June, 2025

Read more
Torpedo Pharmaceuticals AG’s Mission is to set a New Standard in Cancer Therapy with Innovative Radiopharmaceuticals

Torpedo Pharmaceuticals AG’s Mission is to set a New Standard in Cancer Therapy with Innovative Radiopharmaceuticals

By Torpedo / 10th April, 2025

Read more
Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)

Andreas Emmenegger new Group Chief Financial Officer (CFO) and Chief Business Officer (CBO)

By Torpedo / 10th September, 2024

Read more
[Terbium-161] Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lutetium-177]Lu-PSMA-617

[Terbium-161] Tb-PSMA-617 radioligand therapy in patients with mCRPC: preliminary dosimetry results and intra-individual head-to-head comparison to [Lutetium-177]Lu-PSMA-617

By Torpedo / 24th February, 2024

Read more
Cleveland Clinic Appoints Prof. Alex A. Adjei, M.D., Ph.D., as Chair of Taussig Cancer Institute

Cleveland Clinic Appoints Prof. Alex A. Adjei, M.D., Ph.D., as Chair of Taussig Cancer Institute

By Torpedo / 30th June, 2022

Read more
Alex A. Adjei is the recipient of the 2021 ESMO Lifetime Achievement Award

Alex A. Adjei is the recipient of the 2021 ESMO Lifetime Achievement Award

By Torpedo / 12th August, 2021

Read more
Radiation doses from Terbium-161 and Lutetium-177 in single tumour cells and micrometastases

Radiation doses from Terbium-161 and Lutetium-177 in single tumour cells and micrometastases

By Torpedo / 19th May, 2020

Read more
Production and characterization of no-carrier-added Terbium-161 as an alternative to the clinically-applied Lutetium-177 for radionuclide therapy

Production and characterization of no-carrier-added Terbium-161 as an alternative to the clinically-applied Lutetium-177 for radionuclide therapy

By Torpedo / 10th July, 2019

Read more
Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

Terbium-161 for PSMA-targeted radionuclide therapy of prostate cancer

By Torpedo / 27th May, 2019

Read more